This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

10-13 November 2020|Austria Center,Vienna, Austria

EUROPE’S #1 FORUM FOR OLIGONUCLEOTIDE AND PEPTIDE LEADERS TO BUILD SUCCESSFUL PARTNERSHIPS AND ACCELERATE NEW PRODUCTS TO MARKET

COVID-19 Update

As our event is still 6+ months out, we are still planning on holding this year’s TIDES Europe meeting on its scheduled dates of 11-13 November in Vienna. It's business as usual for now, and our team continues to closely monitor regulations from local and global health authorities.  Continue to check back for the latest updates.

TIDES OFFERS THE SCIENCE, TECHNOLOGIES AND PARTNERS YOU NEED TO GROW YOUR BUSINESS

400+ OLIGONUCLEOTIDE AND PEPTIDE SCIENTISTS AND EXECUTIVES

Fast-track your oligonucleotide and peptide research to the clinic and beyond by collaborating with leading pharma, biotechs, academia and solution providers from North America, Asia and Europe.

See Who Attended TIDES Europe 2019
40+ CASE STUDIES AND NEW DATA PRESENTATIONS

Hear best practices, lessons learned and important industry developments across the entire spectrum of oligonucleotide and peptide development and production.

View the 2019 Agenda
30+ LEADING EXHIBITORS

Connect with leading manufacturing, technologies, and service providers to drive your promising therapeutic towards commercial success.

See Who Exhibited at TIDES Europe 2019

CROSS-FERTILIZE IDEAS AND BEST PRACTICES WITH RESEARCHERS FROM DIFFERENT DISCIPLINES

The TIDES 2020 agenda format features 5 scientific tracks covering in-depth development strategies, trends and technologies across the entire oligonucleotide and peptide spectrum. In addition, we have 1 partnering track that will keep you ahead of your competition, and work towards collaborations. Your main conference pass includes access to all 6 tracks, allowing your team to create a customized agenda tailored to your company's current challenges

Oligonucleotide Chemistry, Manufacturing & Controls

Comprehensive CMC, analytical, manufacturing and regulatory strategies for both drug substance and drug product to accelerate oligonucleotide product development.

Oligonucleotide Discovery, Preclinical and Clinical

Design oligonucleotides with better drug-like properties to accelerate your products to the clinic and to market. The latest preclinical and clinical updates to benchmark your research and improve your clinical efforts.

Peptide Chemistry, Manufacturing & Controls

Improve process efficiencies and overcome challenges in process development, CMC and manufacturing. Understand regulatory expectations, new technologies and alternative approaches for emerging complex molecules.

Peptide Discovery, Preclinical and Clinical

Explore new frontiers in peptide synthesis, discovery, design and engineering to improve targeting, delivery and drug-like properties. Case studies on the latest preclinical and clinical successes of peptides and peptide-like scaffolds and structures.

mRNA Therapeutics and Genome Editing

Hear updates on discovery strategies, clinical progress and CMC approaches for mRNA therapeutics and vaccines from industry-leading companies. Learn about state-of-the-art technologies for genome editing applications and hear about progress in genome editing delivery

NEW! Partnering Track
  • Keep abreast of the latest success stories – from investment  towards the market’
  • Tackle collaboration – Trends, partnership models and challenges
  • Dive into the impact of the industry M&A on consumers and prices
  • Hear directly from stage I & II biotech companies who are ready to commercialize 
  • Sit in on panel discussions that will build dialogue around relevant topics
  • Connect with 400+ likeminded professionals

CONNECT WITH KEY BUYERS AT TIDES Europe 2020 in Vienna


Whether you're increasing your company profile, launching a new product or creating business development opportunities, we have flexible and tailored solutions that will optimize your investment.  Contact our team today to see a list of pricing and package options: 

(Companies A-I) Michael Dunnet | MDunnet@informaconnectls.com | +1 (857) 504-6732

(Companies J-Z) Michael Moriarty  | MMoriarty@informaconnectls.com |  +1-646-895-7412

Get the latest event updates

Sign up to get the latest event updates and information.

Oligonucleotide & Peptide Whitepapers


We take the time to create these whitepapers to help educate our audience about a particular topic and promote a best practice methodology. Consider these advanced problem-solving guides!

TIDES Highlight Video


Are you curious as to what attending TIDES Europe is like?

See and hear for yourself why our attendees rank TIDES as the #1 meeting to gain the science, technologies and contacts they need to accelerate promising oligonucleotide and peptide products towards commercial success!

Thank You to our TIDES Europe 2019 Advisory Board

Special thank you to our expanded TIDES Europe Advisory Board, who helped bring new content and expertise to this year's conference agenda. 

Peptide Chemistry, Manufacturing and Controls
  • Mimoun Ayoub, Ph.D., Director and Head of North American and Emerging Markets, CordenPharma International, Switzerland
  • Fabrizio Badalassi, Ph.D., Director, Chemical Development, Ferring Pharmaceuticals, Denmark
  • Alastair Hay, Ph.D., Account Manager, Peptide and Protein Technology, Almac, United Kingdom
  • Ewa Kowalska, Chemical Process Development Manager, API Development, Ipsen Manufacturing Ireland Ltd.
  • Vivian Lindo, Head of Analytical Sciences & Associate Director, MedImmune, United Kingdom
  • Leila Malik, Ph.D., CMC Project Manager, Zealand Pharma AS, Denmark
  • Thomas Meier, COO Europe, Bachem AG, Switzerland
  • Neil Thompson, Group Commercial Director, PolyPeptide Group, Sweden
Peptide Discovery, Preclinical and Clinical
  • Waleed Danho, Ph.D., Consultant, Danho & Associates, USA
  • Jesse Z. Dong, Ph.D., Vice President, Peptide Chemistry, Neon Therapeutics, USA
  • Jesper Lau, Ph.D., VP, Protein and Peptide Chemistry, Global Research, Novo Nordisk A/S, Denmark
  • Les Miranda, Ph.D., Executive Director Research, Structural Biology, Molecular Modeling, & Hybrid Modality Engineering, Amgen, USA
  • Bruce Morimoto, Ph.D., Vice President, Drug Development-Operations, Alkahest, USA
Oligonucleotide Chemistry Manufacturing and Controls
  • Nadim Akhtar, Ph.D., Principal Scientist Characterization and Control Strategies, AstraZeneca, United Kingdom
  • Alun Garner, Business Development Manager, Nucleic Acid Solutions Division, Agilent Technologies, Inc., USA
  • Annekathrin Haberland, Ph.D., Director, Regulatory Affairs, Berlin Cures GmbH, Germany
  • Rachel Orr, GSK Associate Fellow, Enablement Manager, GlaxoSmithKline R&D, United Kingdom 
  • Thomas Rupp, Owner & Principal, Thomas Rupp Consulting, Germany
  • Yogesh Sanghvi, Ph.D., President, Rasayan, USA
  • Jessica Stolee, Ph.D., Associate Director, CMC, Biogen, USA
  • David Tew, Project Leader and GSK Senior Fellow, Advanced Manufacturing Technology, GlaxoSmithKline, United Kingdom
  • Sridhar Vaddeboina, Ph.D., Vice President , Analytical Development, Technology Innovation Improvement Management, Nitto Denko Avecia Inc., USA
  • Stefan Vonhoff, Ph.D., Vice President CMC, NOXXON Pharma AG, Germany
Oligonucleotide Discovery, Preclinical and Clinical
  • Troels Koch, Ph.D., Industry Expert, Denmark
  • Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, USA
  • Dmitry Samarsky, Ph.D., Chief Technology Officer, Sirnaomics, USA
  • Punit Seth, Ph.D., Vice President, Medicinal Chemistry, Ionis Pharmaceuticals
mRNA Therapeutics
  • Christoph Kröner, Ph.D., Head of IVAC Mutanome Lead Structure, BioNTech AG, Germany
  • Hari Pujar, Ph.D., Head, Technical Development, Moderna Therapeutics, USA
  • Liza Tritschler, Project Manager, CureVac AG, Germany